BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11106115)

  • 1. A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer.
    Oettle H; Arning M; Pelzer U; Arnold D; Stroszczynski C; Langrehr J; Reitzig P; Kindler M; Herrenberger J; Musch R; Korsten EW; Huhn D; Riess H
    Ann Oncol; 2000 Oct; 11(10):1267-72. PubMed ID: 11106115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer.
    Oettle H; Pelzer U; Hochmuth K; Diebold T; Langrehr J; Schmidt CA; Arning M; Vogl TJ; Neuhaus P; Huhn D; Riess H
    Anticancer Drugs; 1999 Sep; 10(8):699-704. PubMed ID: 10573201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
    Shiah HS; Cheng AL; Hsu C; Hsu CH; Liu TW; Chang JY; Jan CM; Chao Y; Yu WL; Chuang TR; Whang-Peng J; Chen LT
    J Gastroenterol Hepatol; 2006 Mar; 21(3):531-6. PubMed ID: 16638094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
    Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
    J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma.
    Malayeri R; Ghassemboland M; Ranjpoor F; Maadi A
    Hematol Oncol Stem Cell Ther; 2008; 1(4):221-4. PubMed ID: 20058477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
    Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
    Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
    JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
    Pelzer U; Schwaner I; Stieler J; Adler M; Seraphin J; Dörken B; Riess H; Oettle H
    Eur J Cancer; 2011 Jul; 47(11):1676-81. PubMed ID: 21565490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group.
    Pelzer U; Arnold D; Reitzig P; Herrenberger J; Korsten FW; Kindler M; Stieler J; Dörken B; Riess H; Oettle H
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1173-8. PubMed ID: 21400239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
    Correale P; Messinese S; Marsili S; Ceciarini F; Pozzessere D; Petrioli R; Sabatino M; Cerretani D; Pellegrini M; Di Palma T; Neri A; Calvanese A; Pinto E; Giorgi G; Francini G
    Br J Cancer; 2003 Jul; 89(2):239-42. PubMed ID: 12865908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
    Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
    Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V
    JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
    Gill S; Ko YJ; Cripps C; Beaudoin A; Dhesy-Thind S; Zulfiqar M; Zalewski P; Do T; Cano P; Lam WYH; Dowden S; Grassin H; Stewart J; Moore M
    J Clin Oncol; 2016 Nov; 34(32):3914-3920. PubMed ID: 27621395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.